Original-Research: UBM Development AG - from NuWays AG
Classification of NuWays AG to UBM Development AG
Company Name: UBM Development AG
ISIN: AT0000815402
Reason for the research: Update
Recommendation: Kaufen
from: 30.05.2024
Target price: EUR 27.00
Target price on sight of: 12 Monaten
Last rating change:
Analyst: Philipp Sennewald
Market reopening still pending / chg.
Yesterday, UBM released muted Q1 results following the continued standstill on the European real estate transaction market. Yet, the company was able to dispose some smaller non-strategic assets.
Q1 sales increased on a low level by 14% yoy to € 20.4m (eNuW: € 25m) and were predominantly driven by the progress on construction of previously sold projects, which are recognized over time based on the percentage of completion. Q1 EBITDA decreased yoy and came in at € -2.2m. The decline can be mainly attributed to an increase in material expenses, mainly related to construction costs, as well as slightly higher other OpEx, which was mainly due to unfavorable FX-effects.
On a positive note, the company had a promising start to the year regarding the disposal of non-strategic assets. In fact, UBM sold five slots of the Arcus City to a Czech construction company, one building of the Poleczki Business Park to Porr as well as a 15% stake of the Andaz hotel in Prague to IGO, which now holds a 40% overall stake. While no further details were disclosed, the net cash inflow from the transaction should amount to c. € 25m (eNuW). Overall, management is in advanced negotiations to sell further non-strategic assets as it targets a total net volume of € 75m in FY ‘24e. Importantly, no disposal was made below book value, which has to be seen as a clear hint that the trough has been reached.
Despite this, management provided a rather conservative outlook for FY ‘24e as it is expecting a pre-tax loss (eNuW new: € -7.7m), which is however expected to be an improvement compared to FY ’23 (€ -39m). Given that a sudden reopening of the market is still not in sight, we, however, regard this as reasonable despite the positive trends mentioned above.
All in all, we continue to consider UBM to be well positioned for the pending reopening of the transaction market, given its appealing product offering, which is focussed on sustainable real estate projects. In fact, as of Q1, 77% of the company’s € 1.9bn 4-year pro-rata pipeline consists of timber-hybrid projects, which do not only significantly reduce the carbon emissions but also offer cost advantages due to the modular and serial construction. We hence expect UBM’s projects to be meet strong demand once the market reopens, as investors become increasingly under pressure to comply with the EU taxonomy.
The stock remains a BUY, new PT of € 27.00 based on DDM.
You can download the research here:
http://www.more-ir.de/d/29931.pdf
For additional information visit our website
www.nuways-ag.com/research.
Contact for questions
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++
-------------------transmitted by EQS Group AG.-------------------
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.